ASPE

Aspen Neuroscience Inc

13.04

Nov 02 • 3:59 PM ET -1.85 (-12.42%)

13.20

Aftermarket • 7:41 PM ET +0.16 (1.23%)

Healthcare Biotechnology USA Small NASD

Index	-
Market Cap	379.18M
Enterprise Value	655.38M
Income	-
Sales	-
Book/sh	-8.63
Cash/sh	2.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	117
IPO	Oct 30, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	5.24
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.56
Current Ratio	4.56
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	4.46%
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.62%
SMA50	-6.62%
SMA200	-6.62%
Trades

Shs Outstand	29.08M
Shs Float	-
Short Float	-
Short Ratio	-
Short Interest	-
52W High	14.90 -12.48%
52W Low	11.60 12.41%
Volatility	- -
ATR (14)	2.78
RSI (14)	-
Beta	-
Rel Volume	0.45
Avg Volume	1.32M
Volume	596,587

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-11.29%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	14.89
Price	13.04
Change %	-12.42%

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARCH Venture Fund X, L.P.	10% Owner	Nov 02 '26	Buy	15.00	1,200,000	18,000,000	1,200,000	Nov 02 09:50 PM
ARCH Venture Fund X, L.P.	10% Owner	Nov 02 '26	Buy	15.00	133,333	1,999,995	66,667	Nov 02 09:50 PM
ARCH Venture Partners XIV, L.P	10% Owner	Nov 02 '26	Buy	15.00	1,200,000	18,000,000	1,200,000	Nov 02 09:46 PM

Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andres Bratt-Leal in 2018 and is headquartered in San Diego, CA.

Executive ChairmanMr. Faheem Hasnain

PresidentDr. Damien McDevitt Ph.D.

Co-Founder & Member of Scientific Advisory BoardProf. Jeanne F. Loring Ph.D.

Chief Technology OfficerMr. Kim Raineri M.B.A.

Chief Scientific OfficerMs. Xiaokui Zhang Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ASPE

Aspen Neuroscience Inc

Upgrade your Finviz experience